Researchers may not yet understand the mechanism behind recurrent Clostridium difficile infections, but they may have isolated five risk factors, according to a study published in Infection Control & ...

Recurrent C. diff infections linked to higher death rates, research shows Clostridium difficile infection recurrence may increase the risk of death in patients, according to a presentation at the 27th ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...

Diabetes may be an important risk factor for recurring Clostridium difficile, which is occurring more frequently in acute-care hospital settings, according to a study published in the American Journal ...

A study published in JAMA Internal Medicine found patients receiving gastric acid suppressants may be at an increased risk for recurrent Clostridium difficile infections. Rochester, Minn.-based Mayo ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

ATLANTA -- A tapered and pulsed course of vancomycin was not significantly better than a standard course of the drug for treating a first or second recurrence of Clostridioides difficile infection, a ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a ...

Background. Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab, administered concurrently with antibiotics directed against C. difficile ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...